Table 4 RFS from randomization for BRCAwt and other hub genes of significance.

From: Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy

Gene 1

Gene 2

Vigil median RFS (months)

Placebo median RFS (months)

Difference (months)

N

P-value

HR

Vigil

Placebo

BRCAwt

PIK3CAwt

11.47

7.95

3.52

39

26

0.02

0.53

BRCAwt

NF1wt

12.75

8.35

4.40

40

26

0.04

0.59

BRCAwt

ARID1Awt

12.75

7.95

4.80

37

24

0.05

0.59

BRCAwt

MYCNOSwt

13.67

5.72

7.95

27

17

0.03

0.47

BRCAwt

MUTYHwt

12.75

7.95

4.80

38

27

0.03

0.56